BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:29 PM
 | 
Oct 24, 2012
 |  BC Extra  |  Company News

EC approves Xalkori for NSCLC

The European Commission conditionally approved an MAA from Pfizer Inc. (NYSE:PFE) for Xalkori crizotinib to treat previously treated, advanced non-small cell lung cancer (NSCLC) in patients whose tumors...

Read the full 126 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >